BCAT1 and IKZF1 Gene Promoter Methylation Analysis for Colorectal Cancer (Colvera®)
Colorectal cancer is the second most common cause of cancer-related deaths worldwide. Among various risk factors for colorectal cancer development, somatic mutations remain the most common. These somatic mutations are believed to be most commonly caused by epigenetic alterations including DNA methylation. The screening and diagnosis of colorectal cancer has largely relied upon screening stool for hemoglobin which detects bleeding associated with luminal tumors. Although fecal immunochemical tests (FIT) specific for human blood and tests combining FIT with DNA mutational/methylation analysis have improved the sensitivity and specificity of stool testing they still suffer from both false positives and false negatives. Blood based tests such as carcinoembryonic antigen (CEA) have been evaluated for CRC screening but have proven to not be sensitive enough for clinical use.
Recently the detection of circulating tumor DNA (cfDNA) in the diagnosis of colorectal cancer which is independent of the patient’s demographics and smoking status. These assays can successfully detect and identify DNA methylations in colorectal cancer.
Recent research has identified that aberrant methylations in the BCAT1 (branched-chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1) gene promoter regions are found in >95% and 99% of colorectal cancer tissues respectively. While tyhese tests have not demonstrated their utility in screening for CRC they have been suggested in identifying patients with recurrent cancer.
One test that detects these cfDNA methylations is the ColveraTM. The test utilizes a duplex polymerase chain reaction (PCR) technique for the detection of targeted methylated regions in BCAT1 and IKZF1. A study found that Colvera possessed a significantly higher sensitivity but a lower specificity than CEA in detecting stage II/III colorectal cancer. Studies in the US and Australian cohorts observed that Colvera detected more recurrences confirmed radiologically, and furthermore, was not affected by age, gender, ethnicity, and smoking status of the population. Overall, while Colvera may improve cancer recurrence detection it is not recommended for this purpose by the NCCN, ASCO or CAP.
- Colorectal cancer treatment monitoring and management
- Monitoring of colorectal cancer residual disease and recurrence
Negative (No methylation detected)
Whole blood/ K3-EDTA plasma.
Stability
- Ambient: 24 hrs.
- Refrigerated: 3 days
- Frozen: Unstable
- Clin Med Insights Oncol. 2018 May 10 [PMID: 29780264]
- Cancer. 2020 Apr 1;126(7):1460-1469. [PMID: 31909823]
- Mol Oncol. 2022 May;16(10):2031-2041. [PMID: 35000264]
- Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2702-2709. [PMID: 32958500]
- Cells. 2020 Mar 5;9(3):624. [PMID: 32150897]
- J Appl Lab Med. 2017 Sep 1;2(2):165-175. [PMID: 32630973]